drugset / Trial / NCT03852472
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)
RandomizedParallel-groupDouble-blindTreatment
Summary
Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa
Timeline
- Start
- 2018-12-21
- Primary completion
- 2021-01-14
- Completion
- 2021-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avacopan | Small molecule | 10 mg | — |
| Subject | Avacopan | Small molecule | 30 mg | — |